CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications
View Patent ↗The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
1. A compound, which interrupts CD40:CD154 interaction, of the formula:
wherein,
R 9 is selected from the group consisting of C1–5 alkyl-aryl, cycloalkyl and alkenylaryl; wherein the alkyl is optionally substituted with aryl and the aryl is optionally substituted with one to four halogens, aryl, NH 2 or NO 2 ;
R 10 is selected from the group consisting of alkyl and cycloalkyl; and
R 11 is selected from the group consisting of H and alkyl.
2. A compound, which interrupts CD40:CD154 interaction, of the formula:
wherein,
R 9 is selected from the group consisting of C1–5 alkyl-aryl;
wherein alkyl and aryl are optionally substituted with aryl.
3. A compound, which interrupts CD40:CD154 interaction, wherein said compound is selected from the group consisting of:
4. A compound, which interrupts CD40:CD154 interaction, wherein said compound is selected from the group consisting of:
5. A compound, which interrupts CD40:CD154 interaction, wherein said compound is selected from the group consisting of:
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 – 5 .